These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 26147319)
1. Refractory highly disfiguring lupus pernio: a dramatic and prolonged response to infliximab. Blanco R; González-Gay MA; González-López MA; Fernández-Llaca H; González-Vela MC Int J Dermatol; 2015 Aug; 54(8):e321-2. PubMed ID: 26147319 [No Abstract] [Full Text] [Related]
2. Short course of infliximab for disfiguring lupus pernio. Kiorpelidou D; Gaitanis G; Zioga A; Bassukas ID Eur J Dermatol; 2008; 18(6):727-9. PubMed ID: 19049948 [No Abstract] [Full Text] [Related]
3. Successful long-term management of refractory cutaneous and upper airway sarcoidosis with periodic infliximab infusion. Rosen T; Doherty C Dermatol Online J; 2007 Jul; 13(3):14. PubMed ID: 18328208 [TBL] [Abstract][Full Text] [Related]
4. Cutaneous sarcoidosis and infliximab: evidence for efficacy in refractory disease. Tu J; Chan J Australas J Dermatol; 2014 Nov; 55(4):279-81. PubMed ID: 23651297 [TBL] [Abstract][Full Text] [Related]
5. Disfiguring cutaneous manifestation of sarcoidosis treated with thalidomide: a case report. Lee JB; Koblenzer PS J Am Acad Dermatol; 1998 Nov; 39(5 Pt 2):835-8. PubMed ID: 9810910 [TBL] [Abstract][Full Text] [Related]
6. The treatment of lupus pernio: results of 116 treatment courses in 54 patients. Stagaki E; Mountford WK; Lackland DT; Judson MA Chest; 2009 Feb; 135(2):468-476. PubMed ID: 18812454 [TBL] [Abstract][Full Text] [Related]
7. Infliximab as a steroid-sparing agent in refractory cutaneous sarcoidosis: single-center retrospective study of 9 patients. Sené T; Juillard C; Rybojad M; Cordoliani F; Lebbé C; Morel P; Tazi A; Guibal F J Am Acad Dermatol; 2012 Feb; 66(2):328-32. PubMed ID: 22243729 [No Abstract] [Full Text] [Related]
8. Lupus pernio: successful treatment with a potent topical corticosteroid. Khatri KA; Chotzen VA; Burrall BA Arch Dermatol; 1995 May; 131(5):617-8. PubMed ID: 7741556 [No Abstract] [Full Text] [Related]
9. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases. Heidelberger V; Ingen-Housz-Oro S; Marquet A; Mahevas M; Bessis D; Bouillet L; Caux F; Chapelon-Abric C; Debarbieux S; Delaporte E; Duval-Modeste AB; Fain O; Joly P; Marchand-Adam S; Monfort JB; Noël N; Passeron T; Ruivard M; Sarrot-Reynauld F; Verrot D; Bouvry D; Fardet L; Chosidow O; Sève P; Valeyre D JAMA Dermatol; 2017 Jul; 153(7):681-685. PubMed ID: 28564695 [TBL] [Abstract][Full Text] [Related]
10. [Methotrexate for the treatment of patients with chronic cutaneous sarcoidosis: 4 cases]. Gary A; Modeste AB; Richard C; Jubert C; Majour F; Nouvet G; Remond B; Joly P Ann Dermatol Venereol; 2005; 132(8-9 Pt 1):659-62. PubMed ID: 16230915 [TBL] [Abstract][Full Text] [Related]
11. Complete reversion of anti-infliximab immunization by methotrexate combination in a patient with psoriasis. Vincent T; Best M; Plawecki M; Girard C J Dermatol; 2015 Oct; 42(10):1030-1. PubMed ID: 26119228 [No Abstract] [Full Text] [Related]
12. Extensive cutaneous sarcoidosis and coexistant Crohn disease with dual response to infliximab: case report and review of the literature. Chung J; Rosenbach M Dermatol Online J; 2014 Dec; 21(3):. PubMed ID: 25780977 [TBL] [Abstract][Full Text] [Related]
13. Infliximab therapy for sarcoidosis (lupus pernio). Haley H; Cantrell W; Smith K Br J Dermatol; 2004 Jan; 150(1):146-9. PubMed ID: 14746631 [TBL] [Abstract][Full Text] [Related]